, , , , . Incidence and 10 year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40:394–9.
 , , , , . Volume of intracrerbral hemorrhage: A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987–93.
 , . Hypertensive intracerebral hematoma. An investigation of the initial hemorrhage and rebleeding using chronium cr 51-labeled erythrocytes. Arch Neurol. 1974;30:412–14.
 , , , et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1–5.
 , , , et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.
 , , , et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.
 , , , , . The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–4.
 , , , et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.
 , , , et al. Early neurologic deterioration in intracerebral hemorrhage: Predictors and associated factors. Neurology. 2004;63:461–7.
 , . Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke. 2010;40:3275–80.
 , , , . Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med. 1999;27(3):617–21.
 , , , et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767–74.
 , , , et al. Delayed intraventricular hemorrhage is common and worsens outcomes in intracerebral hemorrhage. Neurology. 2013;80(14):1295–9.
 , , , eds. Intracerebral hemorrhage. Stroke: Pathophysiology, Diagnosis, and Management. 4 ed: Philadelphia: Churchill Livingstone, 2004.
 . Intracerebral hemorrhage: Pathophysiology and therapy. Neurocritical Care. 2004;1:5–18.
 , , , . Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke. 2006;37:2457–62.
 , , , et al. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke. 2005;36:86–91.
 , , , . Matrix metalloproteinases in human spontaneous intracerebral hemorrhage – an update. Cerebrovasc Dis. 2012;34:249–62.
 , , , et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: Relationship to clinical and radiological outcome. Stroke. 2004;35:1316–22.
 , , , et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40:2398–401.
 , , , et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006;67:94–8.
 , , , . Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg. 2007;106:250–4.
 , , , et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129–33.
 , , , et al. Determinants of intracerebral hemorrhage growth: An exploratory analysis. Stroke. 2007;38:1072–5.
 , , , et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology. 2007;68:889–94.
 , , , et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: The spot sign score. Stroke. 2009;40:2994–3000.
 , , , et al. Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage, a prospective study of 139 cases. Stroke. 2011;42:3441–6.
 , , , et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol. 2012;11:307–14.
 , , , , . Surgical treatment for intracerebral hemorrhage (STICH): A single-center, randomized clinical trial. Neurology. 1998;51:1359–63.
 , , , , . Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology. 2001;56:1294–9.
 . Priorities for clinical research in intracerebral hemorrhage. Report from a National Institute of Neurologic Disorders and Stroke Workshop. Stroke. 2005;36:e23–e41.
 , , , et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013; May 29.
 , . Surgical treatment of intracerebral haemorrhage. Curr Opin Crit Care. 2007;13:169–74.
 , , , et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: A randomized study. J Neurosurg. 1989;70:530–5.
 , , , , . A new modified intracerebral hemorrhage score for treatment decisions in basal ganglia hemorrhage – a randomized trial. Crit Care Med. 2008;36:2151–6.
 Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008;118:176–87.
 , 3rd, et al. Nursing at AHASCaCoC. Guidelines for the management of spontaneus intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Assiciation. Stroke. 2010;41:2108–29.
 , , , et al. Blood pressure management in acute intracerebral hemorrhage: Relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364–7.
 , , , et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (interact): A randomised pilot trial. Lancet Neurol. 2008;7:391–9.
 , , et al., and the ATACH investigators. Antihypertensive treatment of acute cerebral hemorrhage (ATACH). Critical Care Medicine. 2010;38:637–48.
 , . Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011;15(3):559–76.
 , , , , . Rapid blood pressure reduction in acute intracerebral hemorrhage: Feasibility and safety. Neurocrit Care. 2008;8:316–21.
 , , , et al. Impaired cerebral vasomotor activity in spontaneous intracerebral hemorrhage. Stroke. 2009;40:815–19.
 , , 3rd, , et al. Guidelines for the management of spontaneous intracerebral hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.
 , , , et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 update. A guideline from the American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:e391–413.
 , , , et al. Recommendations for the management of intracranial haemorrhage – part 1: Spontaneous intracerebral haemorrhage. The European Stroke Initiative writing committee and the writing committee for the Eusi Executive Committee. Cerebrovasc Dis. 2006;22:294–316.
 , , , et al. Autoregulation of cerebral blood flow is preserved in primary intracerebral hemorrhage. Stroke. 2013;44:1726–8.
 , , , , . Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008;39:3029–35.
 , , , et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996;347:422–5.
 , . Complications of intracerebral haemorrhage. Lancet Neurol. 2012;11:101–18.
 , , , et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 2009;8:434–40.
 , , , et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–85.
 , , , et al. Efficacy and safety of recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.
 , , , et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–21.
 , , , , . Warfarin, hematoma expansion and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.
 , , . Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471–7.
 , , , . Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology. 2000;55:947–51.
 , , , et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92.
 , , , et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.
 , , , et al. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages – the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex – study design and protocol. Int J Stroke. 2011;6(3):271–7.
 , , , . Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1991;54:466–7.
 , , , , . Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710–11.
 , , , , . Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004;35:1415–20.
 , , , , . Optimal timing of resumption of wafarin after intracranial hemorrhage. Stroke. 2010;41:2860–6.
 , , , et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
 , , , et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.
 , , , et al. Recommendations for the emergency management of complications associated with new direct oral anticoagulants (doac) apixaban, dabigatran, and rivaroxaban. Clinical Res Cardiol. 2013;102:399–412.
 , , , et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–9.
 , , , et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
 , , , , . Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011: 124.
 , , , . Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43.
 , , , et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.
 , , , et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.
 , , , , . Treatment of acute intracerebral hemorrhage with e-aminocaproic acid – a pilot study. Neurocritical Care. 2004;1:47–51.
 , . Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid. Nephrol Dial Transplant. 2000;15:107–9.
 , , , , . Stereotactic aspiration-thrombolysis of intracerebral hemorrhage and its impact on perihematoma brain edema. Neurocrit Care. 2008;8:322–9.
 , , , et al. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–51.
 , , , et al. Safety and tolerability of nxy-059 for acute intracerebral hemorrhage: The chant trial. Stroke. 2007;38:2262–9.
 , . Tuftsin fragment 1–3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke. 2005;36:613–18.
 , , , et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab. 2006;26:536–44.
 , , , et al. Erythropoietin reduces perihematomal inflammation and cell death with enos and stat3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006;96:1728–39.
 , , , et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis. 2007;26:464–72.